VRTX · 8-K · 20261102PR000287

Acquisition / Partnership / Divestiture

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 71 · Surprise 60

Vertex completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, for approximately $10.0 billion in equity value, or $9.0 billion net of cash, cash equivalents, and marketable securities acquired. The acquisition established Vertex’s fourth commercial pillar in rare endocrine diseases and added PALSONIFY, which generated $10 million of September revenue. Vertex recorded $502 million in third-quarter acquisition-related compensation and transaction costs and borrowed $4.5 billion through a term loan during the quarter. Separately, Vertex entered a collaboration with AbCellera in July and made a $28 million upfront payment.

Key facts

• Vertex completed its Crinetics Pharmaceuticals acquisition in September for approximately $10.0 billion of total equity value, or $9.0 billion net of acquired cash, cash equivalents, and marketable securities. source
• Vertex entered into a collaboration with AbCellera in July and made a $28 million upfront payment. source